At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.
In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.
Mandziuk is vice president, project management, eClinical Development & Delivery, at ICON and she says nothing could have prepared the health industry for the global impact the Covid pandemic has had.
Curve Therapeutics, a biotech developing an intracellular screening platform addressing complex disease targets, has closed its £40.5 million Series A financing.
Jane Kendrew changed paths after a year of her first degree knowing it was exactly the right way for her. She left university with a first class honours degree and turned down the offer of a PhD to start her dream job as a research scientist.
A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.
Glox Therapeutics, a company developing precision antibiotic therapies based on naturally occurring bacteriocins, has raised £4.3m in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
Children’s Mercy Kansas City, an independent pediatric health organization, has become the first health care system to replace old genetic tests, such as rapid exome and chromosomal microarray analysis, with the world’s most-advanced genomic sequencing...
Evozyne has announced the closing of an $81 million series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.
X-Chem, a company focused on drug discovery services, and the Structural Genomics Consortium (SGC), a public-private partnership accelerating drug discovery through open science, have partnered to create new chemical tools to study human proteins.
Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...
Kiora Pharmaceuticals has been granted US and European patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.
A research team led by University of California, Irvine scientists has developed an ‘innovative’ method for quickly creating vast collections of chemical compounds used in drug discovery by using ribosomes, the molecules found in all cells that synthesize...
Talus Bioscience, a drug discovery company developing new treatments for cancer, inflammation, and other diseases, has announced $4.3 million in non-dilutive grant funding across three new awards.
Sigma Mostafa is the chief scientific officer of KBI Biopharma, a development and contract manufacturing organization serving the biopharmaceutical industry.
London-based precision medicine software provider Lifebit has partnered with two population genomic initiatives in Mexico and Brazil to help diversify genomic research and reduce health inequality in Latin America.
BenevolentAI, a clinical-stage AI development company, has announced the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.
Moderna will explore next generation technologies - including quantum computing and artificial intelligence - to advance and accelerate mRNA research via a new partnership with IBM.
The Danish biotech Adcendo has bagged a Series A extension round of €31 million ($33.8 million), taking its Series A winnings so far to €82 million ($89.5 million). The round will bankroll the development of Adcendo’s pipeline of antibody-drug...
The White House releases a report detailing how it will harness biotechnology and biomanufacturing to address numerous societal challenges, including human health.
Infinimmune, a biotech pioneering new methods for antibody drug discovery and development, has closed a $12 million seed round: helping it develop its R&D capabilities.
BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.
Apollo Therapeutics and The Institute of Cancer Research in London have entered into a strategic collaboration to discover and develop new cancer medicines.
Sanofi and Insilico Medicine have announced a multi-year, multi-target strategic research collaboration: leveraging Insilico’s ‘Pharma.AI’ platform to advance drug development for up to six new targets.
Colossal Biosciences spins out Form Bio, which emerges with funding and a software platform that is designed to be used across drug discovery, cell and gene therapy, manufacturing, and academic research.
UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
The initiative is seeking proposals from final year MD, PhD students and postdoctoral researchers in relation to drug discovery and development across AstraZeneca’s core disease areas.
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies...
Semarion Ltd, a University of Cambridge spin-out company combining materials engineering and cell biology to tackle unmet drug screening needs, has just closed a £2.14m (US$2.89m) seed funding round.
Australia company, Inventia Life Science, which is focused on advanced 3D cell cultures for research and clinical purposes, has just closed a US$25M Series B funding round, led by Blackbird Ventures.
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.
AION Labs, a ‘first-of-its-kind’ innovation lab that will create and adopt AI technology to transform the process of drug discovery and development, has officially launched this month.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
Harbour BioMed and an unnamed ‘leader’ in immunology enter license agreement to develop, discover, and commercialize biologic therapeutics using the former’s transgenic mouse platform.
